According to a recent LinkedIn post from Cagent Vascular Inc, a Hartford HealthCare vascular surgeon used the company’s Serranator device in two sizes to treat a complex peroneal-through-plantar occlusion. The post indicates that low inflation pressures were used, with controlled luminal gain and restoration of blood flow to the foot.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The same clinician is described as the principal investigator of a newly published study in the Journal of Endovascular Therapy, characterized in the post as the largest series involving a specialty balloon in inframalleolar vessels. The LinkedIn content highlights a reported 89.9% rate of wounds healed or improved at six months, which may support the clinical credibility and adoption prospects of the Serranator platform.
For investors, this type of clinical use case and peer-reviewed publication may signal progress in evidence generation for below-the-ankle interventions, a segment with high unmet need in limb salvage. Strong clinical data, if corroborated and translated into guidelines or broader practice, could enhance Cagent Vascular’s competitive positioning and potentially support pricing power and market penetration in endovascular therapy.
The reference to an associated press release suggests an effort to raise visibility among clinicians, hospital systems, and potential strategic partners. Over time, wider clinical uptake and validation in real-world settings could influence revenue growth prospects and make the company a more attractive candidate for partnerships or acquisition within the vascular devices space.